These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12059988)

  • 21. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
    Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
    Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
    Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
    Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
    Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
    Lins RL; Matthys KE; Billiouw JM; Dratwa M; Dupont P; Lameire NH; Peeters PC; Stolear JC; Tielemans C; Maes B; Verpooten GA; Ducobu J; Carpentier YA
    Clin Nephrol; 2004 Oct; 62(4):287-94. PubMed ID: 15524059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.
    Chan DC; Nguyen MN; Watts GF; Ooi EM; Barrett PH
    Am J Clin Nutr; 2010 Apr; 91(4):900-6. PubMed ID: 20181806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
    Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
    Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
    Vansant G; Mertens A; Muls E
    Acta Cardiol; 2001 Jun; 56(3):149-54. PubMed ID: 11471927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia.
    Matafome P; Monteiro P; Nunes E; Louro T; Amaral C; Moedas AR; Gonçalves L; Providência L; Seiça R
    Pharmacol Res; 2008; 58(3-4):208-14. PubMed ID: 18692137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
    N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S; Geiss HC; Otto C; Parhofer KG
    Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
    Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.